Risedronate sodium is a pyridines derivative drug which belongs to the class of bone density conservation agents.
Risedronate sodium is indicated for treatment and prevention of osteoporosis in postmenopausal women, glucocorticoid-induced osteoporosis in men and women and treatment of osteoporosis in men, and also used for treatment of Paget's disease of bone.
It is formulated as tablets, film-coated tablet for oral route of administration.
Mechanism of action:
Risedronate sodium is a pyridinyl bisphosphonate that binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. The bone turnover is reduced while the osteoblast activity and bone mineralization is preserved.